“… 3 Our previous study has demonstrated that BCL11B mutation is associated with favorable clinical outcomes in patients with T-cell lymphoma (TCL). 9 Although both T-ALL and TCL belong to T-cell malignancies, there are significant differences between them on the origin of malignant T cells, genetic background, mutation landscape, and treatment options. Therefore, the prognostic value in this study was similar to the published articles on different types of diseases.…”